Back to results

Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma

Objective

To demonstrate superiority of Arm A: fianlimab (REGN3767) + cemiplimab compared to Arm B: relatlimab + nivolumab as measured by ORR.

Protocol #

R3767-ONC-22122

Trial Phase:

Phase III

Principal Investigator:

Poklepovic, Andrew

Cancer Type
  • Melanoma
  • Skin
Study Site
  • Virginia Commonwealth University

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Tyler Phillips
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: